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A New Experimental Approach to the Specific Adoptive 
Immunotherapy for Malignant G liomas 
TOSH I KI¥' AMASAKI 
Department of Neurosurgery, Kyoto University, '.¥Iedical School 
(Director: Prof. Dr. HAJl'.v!E HANDA) 
The ef五cacyof tumor-specific cytotoxic T lymphocyte clone in the specific adoptive immuno-
therapy for a syngeneic murine malignant glioma (a methylcholanthrene-induced ependymo-
blastoma of C57BL/6 mouse origin, 203-glioma) was investigated. Two clones （（トCTLL1 and 
2) were established by a limiting dilution technique (0.3 cells/well in 96 well microtiter plate) 
with the aid of T-ce¥l growth factor (TCGF). 
TCG F was prepared and assayed as follows; 5×106/ml rat or murine lymphocyt肘 werecul-
tured with 2 μg/ml concanavalin A (Con A) in RPMI-1640 medium supplemented with 2 ~。 fetal
calf serum for 48 hours. The culture supernatants (Con A sup) were concentrated by ammonium 
sulphate precipitation and partially puri五edby successive DEAE (diethylaminoethyl)-cellulose 
ion exchange chromatography and Sephadex G-100 gel filtration. Assays for TCGF activity 
were performed for a quantitative analysis using G-CTLL 1 cels. 
（； CーTLL1 cel line which showed much higher cytotoxic activity against 203-glioma cells 
was further analyzed in vitro and in vivo. In vitro, G-CTLL 1 cells were maintained in TCGF-
dependent exponential proliferative growth for over 15 months and continued to mediate extreme 
ly high cytotoxic activity against 203-gliom乱cells(50 to 100 fold increases over the peak cytotoxic 
activity of sensitized T lymphocytes in tumor-bearing mice). They also revealed a weak cytotoxic 
activity against RおV-¥I(a Schmitt-Ruppin Rous sarcoma virus induced malignant glioma of 
C3H/He mouse origin) cels. However, this line had no cytotoxic activity against other syngeneic 
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EL4 thymoma, ＼＇＼ト 12fibrosarcoma、B-16malignant melanoma, and allogeneic P815 masto-
cytoma, Yλ（ :-1 T cell lymphoma and C -1300 neuroblastoma cels. Therefore令 G-CTLL1 cell 
line seemed to exhibit a murine glioma-specific cytotoxicity. The surface phenotypes of C-CT I ,L 
1 cells lり’ anegative selection method using a complement dependent cytotoxicity assay were 
determined to be Thv-1大Lyt-1.2十.3+and川 ialoG¥!1一， thoughThy-1 antigen disappeared gra-
dually in repeated subcultures. Their cytotoxicity W<t、blockedby adding only anti-Lyt 2 
monoclonal antibody. Therefo問、theseresults are compatible with a theory that Lyt-2 expression 
on cytotoxic T lymphocyte (CTL) is correlated with the nature of the antigenic determinant or 
antigen recognition structure and that thi,; molecule may play an essential role in the differentiat-
ed function of （、TL.
( ;-CTLL 1 cells were found to 'ecrete immune interferon (IF~ ） by stimulating with mitogen 
（（冶nAl or tumor antigen (203 glioma or RSV :¥1). Immune IF:¥ may be produced by G CTLL 
1 cells in response to murine glioma-associated antigen specific stimulation. These results rn灯
suggest that in tumor killing proce" C; CTLL 1 cells can deliver a "one-two punch" at a local site; 
the death to a target cell and the local re le川 eof immune IF:¥, which may inhibit the tumor growth 
or enhance the ac、tivityof killer mechanismsはtthe site of a< ;-CTLL 1-target recognition event. 
¥Iorphologically, < ,-CTLL 1 cells appeared to be large granular lymphocytes with prominent 
azurophilic granules. 
じ（、TLL1 cells were able to recover from cryopreserved stocks and to be re-established in 
long-term culture retaining immunological 《h川出teristicswithout the loss of target specificity目
Immunobiological properties of TC(; F were also characterized in murine and rat Con A sup, 
respectiveiy. The major portion of T< '(; F activitv in murine and rat℃on A sup was recovered 
in the 50 to 80°＂町 40to 80"" (:¥H.1)2S0.1 fraction, respれ、tivぞly. These activities were found in 
proteins of 30 to 36司000、12to 18,000 daltons size 川 estimatedhv gel filtration, respectively and 
eluted from ion exchange chromatography in a ＇.＼＇川、 lgradient on 0.15 ¥l、0.05¥[. re≫ pet、tivclv.
It was found that rat （三mA sup contained ’打、CFactivitv approximately 8 timesぉ muchas 
murine Con A sup. 
The in vivo systemic treatment of intracranial tumor bearing mice is a for better test of the 
therapeutic potential of<; ("fl ,L 1 cell line. though some immunotherapy protocols have utilized 
a Winn type neutralization assay (the admixture of じぐTLL1 and tumor cells in vitro prior to 
the in vivo adoptive transfer). In the adoptive immunotherapy study, al 24 mice except one have 
survived for over 15 weeb when transferred 2 or 5×107 （；ーCTLL1 cells intravenously by the 7th 
day after the intracranial tumor cell inoculation. A standard model of intracranial tumor bearing 
mice日出 madeby inoculating intrはcraniallywith 5×1Q5 203-glioma cells. All mice died with 
a median survival time （九！ST)of 3.2 wぞぞい The considerable therapeutic effects were largely 
dependent on dose and time of intravenous administration. < lnthe contrary, the infusion of 
町 n,;itizedsplenic T lymphocytes from tumor bearing donors resulted in a decrease of ¥l ST, 
suggesting 、tronglythat suppressor T代ιlbor their precursor cells exi't and regulate the immune 
r叶 J0l1引・sin a tumor bearing host. 
This new experimental approach to the specific adoptive immunotherapy with tumor-spec1凸r
悪性グリオー7IC対する特異的免疫療法への展望 785 
cytotoxic T lymphocyte clone and TCG F may be particularly useful for malignant gliomas because 
gliomas do not usually metastasize to other organs. :¥Ioreover, it is expected that modifications 
of these techniques may be applicable to th巴therapyof human malignant gliomas 
1. はじめに
脳腫蕩の免疫監視機構ic関して，従来より脳は“a




























































induced thymoma), YM-12 (a methylcholanthrene-
induced日brosarcoma),B-16 (a spontaneous mali-
gnant melanoma）および異系腫湯の P815(a methyl-
cholanthrene-induced mastocytoma of DBA/2 mouse 
origin). YAぐ 1ー(a moloney leukemia 、・irus-induced
T cel lymphoma of A ;Sn mouse origin), C-1300 (a 
spontaneous neuroblastoma of A 'j Ax mouse ori-
gin), RSV-'.Vl (aSchmitt-Ruppin Rous sarcoma virus・ 
induced malignant glioma of C3H 'He mouse origin) 
を用いた．
なお YI¥1-12,B-16, C-1300, RSV-M ！ま 0・MI-: NI




培養 203-glioma細胞を 0.I v0 trypsinおよび 0.01
9ぢ ll>TA (ethylenediaminetl'traacetico acid) 添加
phosphate-buffered saline (I’Bメ， N九Cl: 8. 0 g/l, 
NむHド01.1.15 g//, KCI; 0. 2 g//, KH,1'0,: 0. 2 g// 




スの平均寿命（mediansurvival time, MST, 50~ちの動
物が死亡するまでの期間）は3.2週であった73>.
3. i1 TCGFの調整 7 ウス牌細胞あるいはラッ
ト牌および腸間膜リンパ節細胞5×106/m／を 2μg/m/
concanavalin A (Con A, Pharmacia, Sweden）および
2% FCS添加 RI’＼11-1640培地で州｜寺間培養した．
遠心（10,000 rpm, 20分）の後，培養上清（ConA sup) 
をf't. i'こ l"• .J11 A sup中から ConAを除くために次の
操作を行なった． ラット ConA supを0.1mM !Vig-
Chおよび 0.1 mM ¥foCJ,を含む 20mMPBS (pH 





ット f‘onA supを硫安分爾した 予備的lζConA 
sup 5 m/ lζ各々固形硫安を加え o~ちから 10, 20, 30, 
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100 
%飽和までの16段階の分画をお乙なったー一晩放置
後，生じた沈殿を遠心（10,000 rpm, 20分， 40（、）によ
り1巨〆，PBSIζ溶かした後．透析をおこなった．第二
段階として，硫安分画により得た活性画分を 20mM
sodium phosphate buffer (ph 7. 4, NaPB）に対し透
析をおこなった後，あらかじめ同緩衡液で平衡化した
DEAE (diethylaminoethyl)-celluloseカラム（径 2.3
cm×長さ 16.0 cm) IC吸着させた．カラムを同緩衡液
で洗浄したiん吸着物を；－.；，氏、lの直線濃度勾配（0.01 
-0. 5 M）によって的出した．各フラクション（7.4ml) 
の N汁CJ濃度は．電気伝導度を測定し，あらかじめ作
成した検量線より求めた．第三段階として，第二段階
の活性画分をポリエチレングリコー ル（韓PEG20, 000) 
により濃縮し， PBSlζ対し透析した後，おephadex
(;-100カラム（径 3.2cm×長さ 96.0 cm）のケツレ炉
過をおこなった．分子量のマーカーとしては， bovint" 
serum albumin (BSA, m. w. 68, 000), oval bum in 
1< J¥' A, m.w. 44, 000), myoglobin I ;¥IV<"l. m.w. 18, 000) 
を用いた．
ii1 TCGFの活性測定：各段階で得られた試料は，








トーに倍数希釈した（1/2,!14, 1/8, 1/16, 1/32, 1/64) 
sample 100 μ／を加え， 24時間培養後， G-CTLLl細
胞の生存細胞数を trypanblue dye exclusion method 
lこて算定し倍数希釈曲線を作成した その倍数希釈曲
線から 1/2希釈時の5096牛存細胞数に必要な濃度希釈






×106/0. 5 m／を responderとし，皮下移植6週自に
850 rad照射（invivo）した 2日後の7 ウス牌細胞5×
l04i0. 5 m／を antigenpresenting cel とし， 平底24
穴プレートで培養開始した.3日日に 30%Con 人，
free sup Im／を添加し， 6日目IC他の平底24穴プレー




た．さらに，希釈限界法（0.3 cel>/ well in 96-well 
microtiter plate）により一次クローンのモノクローン
化（二次クローン； G-CTLL）をお乙なった．すなわ
ち， 305ぢCM(conditioned medium; Con A supを
30%含む RPMI-1640完全培地）ならびに antigen
presenting cel (2 ;-: 105/m／）とともに 100μ／で平底96
穴7イクロプレートを用い培養開始した. 4日目， 8
日自に 30% C'.¥1を 100μ／添加し増殖してくるク ロ
ーンを12～16日自に pickup し．以後平底24穴プレ
トー ICて 305ぢCM 存在下lと継代培養をおとなった．
5. 腫場細胞障害性試験
203-gliomaをはじめ YM12, B 16，ぐ 1300およ
び RSV-M細胞は， トリプシンと EDTA処理をお
こなわなければ浮遊化できず，その処理ーによって腫務






理（50μg/m1, 45分間）をおとなった targetcel とG-
CTLL (effector to target cel, E: T, ratio=2: 1,10: 1) 
の18時間混合培養後に生存する targetcellを trypan 
blue dye exclusion method で求め，次の算式から
CTL活性を測定した．
CTL activity （必）＝
~urvivi~g tar15et cells obtained after 
1th G-CTLL cells 
(l-surviving target cells obtained after ）×100 
incubation with medium alone 
なお， GCTLLはTCGF非存在下では約12時間で
90 Oc仏 18時間では98%が死滅するので targetcel 
count には殆んど影響がなかった．
6回 表面マーカーの検索
G-CTLLの膜抗原は， a）抗 Thy1, b）抗 Lyt1, 






trypan blue dye exclusion method Kて各抗体処理後
における G-CTLLの生存細胞数を求め，次の算式よ
り各々 の cytotoxicindexを表示した．
Cytotoxic index （箔）＝（l ~）× 100 
A : thepercentage of viable G-CTLL cells after 
lysis by antibody plus complement 
B : thepercentage of viable G CTLL cells after 





世用するモノクロナーノレ抗体の力価は，各々 a)1 μg1 
ml 101牌細胞， b）および c)10 μg/ml 106牌細胞，







lar stomatitis virus, VSV）の細胞毒性法（convention-
al cytopathic effect, CPE, inhibition assay）により測
定したBlー すなわち， L細胞 3×104/wellを96穴平氏
7 イクロプレートに分注し，段階希釈した試料を 100






















50mM KClを 1N HClで ph2. 0 に調整した緩
衡液に対し，試料を透析（4'C,24時間）した筏，続い
て 20mM PBS (ph 7. 4）に対し透析（4。C,24時間）し
た．対照は， 20mM PBS (ph 7. 4）に対し透析（4'C,
48時間）した
上記， ph2. 0 処理試験をおこなった i~. lFN活性
を測定した．
10. 担脳腫揚動物に対する G-CTLL1の抗腫痕効果




G-CTLLl 1×106または 5×106個（すなわち， E:T
ratio=2: 1または 10:1）を混合して移植した担脳腫
場動物の生存日数を観察し， 九！ST, TDR (tumor 
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death rate at 8 weeks，腫場移植後8週までに死亡す
る比率）， I) r (number of mice died after tumor cell 




i) 移入試験（systemicadoptive transfer '1s,ay) 
a）移入するじく、TLLlの有効投与数をみるため，
203-glioma細胞 5×105個を頭蓋内に移植した担脳腫
蕩動物に対し．移植後7日自に G-CTLL1 1×106, 





脳腫場動物iζ対し，種々の時期ICG-CTLL 1 1×10' 





Table l. Cytotoxic dどrw巾 ofD-C T LL cells against 
203 ''ltonuz cells 




67.9ネホ 87. ~ J** 
b 47. 7** 67. 7** 
c 46. 4* I 56. 6ホ
じ（、TLL
l 58. 2* ' 82. 6** 
2 44. 6* ' 68. 4 ＊ホ
3 10. 8 I 12. 5 
4 8. o I 12. i 
5 12. O I 8. 1 
じぺ TLL1and2 cels仁xhiuiteda signi白cantcytotoxi仁
川 tiYityag剖nst203・gliomacells, though 5 clones ¥'ere 
obtained from primary clone "a" which possessed 
much more % lysis than other clones川 Ii"and “c” 
九日luc,are叫ati、tic：ιilysigni日cant
（キpく0.01，本＊p日 0.005).
TC< ;i: T-cell growth factor. 
< ;.('Tl.l. glioma speci品ccytotoxic T lymphocyte clo 
ne. 
E T: effector to target cel ratio. 




分離された 3株の一次ク ローンのうち 203-ghoma
細胞に対し CTL活性を最も強度に示した＂ n＇’を ク
ローニングした結果， 5株の二次クローンが得られた
(cloning ef品ciency:5. 2,Sぢ）．とれら 5株の二次クロー
ンはいずれも TC心F依存性に exponentialIC増殖し
たが， 203-glioma細胞に対し CTL活性を示したも






























o--<> G-CTLL I 
G-CTLL 2 
~ G CTLL3 
4 6 8 10 12 
Time in culture (days) 
Fig. l. Gγowth turle芯。fC-CTLL cells 同行In>
¥¥'h<'n seeded at a concentration of 5×103 
cels per m人GCTLL 1 . 2 and 3 cels reach 
, saturation density of approximately 3×105 
cells per ml after 6 or 7 days in culture, de-
monstrating a doubling time of approxima-
tely 24 hours. The proliferative gn川 this 
totally dependent on the presence of TC(; f 
G-CTLL: glioma-specific cytotoxic T lym-
phocyte clone. 
TCG F: T-cell growth factor. 
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フィーでは 150mM, 50 mM N aCIの位iQ'Iこ溶出され
(Fig目 2a, b), Sephadex G-100ゲJレj戸過法では分子量
3.3万， 1.5万の位置に溶出された（Fig.3 a, b）.また，




G-CTLL 1は， ConA sup中の TCGFlζ依存性
lζ約24時間の倍加時間で増殖した（Fig.1). 
G-CTLL 1 を用いマウスおよびラノトの Con A 
sup中に含まれる TCGFの物理化学的性質を比較す
ると，各々硫安分画では50～80＜弘 40～80~づで飽和し


















































































i : ¥ 
,PI : ¥ ／：＼一一一－－－－－－－－／－.と二＿＼＇~’ ＼一一一一
5 10 15 20 25 30 35 40 45 50 55 
Fraction number 
ρEAE-cellulose ion exchange ch仰 matographyof murzne (a）乙rrat (bi Con ・1 sup 
The 50 to 80%, or 40 to 80% ( ]',; H4)zS04 precipitate from 200ml murine or rat Con 
A sup was dissolved in 5ml 20m ¥Isodium phosphate bu仔er(pH 7.4) and dialyzed 
twice against 100 volumes of the same buffer before fractionation, respectivelx. 
The samples were applied to a DEAE (diethylaminoethyl)-cellulose column equih 
brated in the same bu百er,respectively. A gradient from 0.01 to 0.5 ¥I NaCl was 
used for elution. The conductivity of each fraction was measured to determine 
the ionic gradient. The fractions were subsequently assayed for TCGF activitv 
（・）. ~Each fraction (7.4 ml) was examined for the optical density at 280 A 
( I and the ；＇＼；正lconcentration ( --0--). 
Tcr；ド T-cellgrowth factor. 
Con A sup: culture supernatant stimulated lw Con A 






























欣に， G-CTLLlは 203gliomaおよび RSV-M細胞
に対し cross-reactivityを示し， 7 ウスグリオ－7fこ対
第52巻
(;.(_"JLLlの 203-glioma細胞に対する CTL活性
は 5.56 lytic units (LL'), l IJハ細胞であり， Tcのそれ
は 0.13LU/106細胞であった（Fig.5）.すなわち，
G-CTLL lは 203glioma細胞に対し強度の CTL活
性を示した．
ii）腫蕩特異性
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Fraction number 
































Sepliadex G-JOOgelfi!iration ofmurine （α） or rat (b) Con .J sup 
Th＂山口、 efractions from DEAE-cellulose ion exchange column containing TC<; F 
activity (fraction 43 to 48 in murine Con A sup, or fraction 25 to 32 in rat Con A 
sup) were pooled, concentrated by polyethyleneglycol (PEG幹20、000)to 10 ml、。－
lume, and dialyzed t¥'i刊 against100 volumes of 20 m ¥I phosphate buffered saline 
(pl! 7.41 before fractionation, respectively目 Thesamples were then applied to a 
Sephadex G 100 column equilibrated in the same buffer, respectively. The column 
M出 calibratedwith the following m.w. (molecular weight) standards: bovine serum 
albumin (68,000 m.v.), ovalbumin (44,000 m田川.) and myoglobin (18.000 m.v.). 
The fractions were subsequently 'lS"1ved for TC<; F activity （－・ー ト Each fr山、
tion 17.4 ml）羽川 examinedfor the optical dens町 at280 A ( ー）．
T< ・c; F T-cell growth factor. 
Con .¥ sup: culture supernatant stimulated by Con A 
Con 人 円川口市川•alin A. 













2 4 8 16 64 32 
ReciprocロIof sロmpledilution 
Fig.も Reiαti'明日歩αct'tyof Co匁 Asup to suppo；γt Fγolzfe：γαt'o汎 oflong-teγm cu/tu：γed 
G-CTLL 1 cells 
Rat Con A sup （・） contained approximately 40 U /ml of TCG F activity. 
On the other hand, murine Con A sup (-0ー） contained approximately 5 U / 
ml. 
G-CTLL: glioma-specific cytotoxic T lymphocyte clone. 
TCGF: T-cell growth factor. Con A sup: culture supernatant stimulated by 







開E垣：ble2. Se歩αγatt'onof TCGF配 tivityf刊概叩urine
andγαt C側 Asup by precipitati閥均 a隅－
m閥均視 SU~歩hate
Co附 n n 0 I Biol骨ic訓示It戸門司Ft ti of I 
（川）2SO, ~ J~ ___J_ljjml) 


















Sequential precipitation with increasing concentration 
of (NH4)2S04 precipitation was performed at 4°C. 
The pelet of material recovered by centrifugation of 
each step was dissolved in 5.0m/ of 20 mM phosphate-
bu官eredsaline (ph 7.4) and dialyzed twice against 
10 volumes of the same buffer. Each samole w aぉ
then assayed in serial 2-fold dilutions for T( ・c; F acti-
vity. The biologic activity is expressed in units as 
descri~ed in i¥IATERIALS A'.¥D :¥IETHODS. 
TCGF: T-cell growth factor. 
Son A叫； culture叫 ernatantstimulated by Con A 
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Tc(0.13LU) 







o＇’ 10 20 30 40 50 
(E:T ratio) 
Fig. 5. Comparison of cytotoxic activity between G-
CTLL 1 and Tc cells 
On Day 35 after starting continuous culture, 
G-CTLL 1 cells showed 5.56 LU /106 cells up 
to 50・to100-fold increases of Tc cells which 
showed 0.13 LU /106 cels. Regional lymph 
node T lymphocytes on Day 14 after tumor 
cel inoculation are referred to as Tc cells, 
which exhibit a peak cytotoxic activity in 
tumor-bearing mice73l. 
Lytic unit (LU) is de五nedas the number of 
effector cells required for 50°10 lysis of 203-
glioma cells within 24 hours. 
G-CTLL: glioma-specific cytotoxic T lvm-
phocyte clone. 
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Table 3. Target specift口・1yof G-CT.よLI cells 
Cytotoxic activity （忽 lysis)
Tumor cel line討 Day56 I D川・210 Day 360 
日＝2:1I E:T=lO:l革 2:1戸司函：iI一日正
203-glioma (H-2h) I 63. 2** I 83. 2** I 60. 6料 I 86. 2** I 62. 4** 80. 8** 
































P815 1H-2d) ! 
IH-2•) I 
:¥D 3. 2 I ND 3. 2 ND 2. 2 
ND 2. 6 I ND 2. 8 I ND 1. 
On Da、56’210and 360 after 刈はrtingcontinuous culture, G CTLL 1 cells exhibited a signi五cant
cytotoxic actiYi勺礼gain'tsyngeneic 203・gliomacells and a mild cytotoxic activity against allogeneic 
］｛ ~Y :'d glioma celk but there was no signi五cantcytotoxic activity against a panel of other 3 syn-
巨cncictumor cel lines, B-16, Y:¥I-12 and EL4, and 3 allogeneic tumor cel lines, C-1300, P815 and 
L¥C 1 (**p<0.005，本P<0.05).
< ;-CTLL 1 cells appeared to continue to mediate a murine glioma-speci五ccytotoxicity. 
( ,-CTLL. glioma-speα凸cC¥"t向toxicT lymphocyte clone. E: T: effector to traget cel ratio. 
:¥I) not done. 
処理した後， 203glioma細胞に対する CTL活性を




じ CTLLlば，少量の IFN(106m／で 26u，叩／，
3×HJ5, mfで 8U.m!Jを培養液中iζ自然放出するが，
mi to genまたは tumorantigen刺激で G-CTLLlの
Table 4. S111プacemar!:cn of C四CTLLI cells 
Tri・atrn1・lit
Viable GぐTLL1 cells （第）
lJ川＜＞5 Dav 56 Ila、180
none 77.9 78.4 80.4 
complement 78.0 76. t, 78.6 
Thy 1 3. :i* 58.3 76.2 
I λl 1 74. 7 76.3 83.8 
I 入l:! 4.0* 6. 2* 5. 2* 
日sialoGM1 78.6 73. 2 76.6 
Surface phenotypes円f（ト（＇TLL1 cells 、ereevaluated 
by a negative selection method using a complement-de-
pendent cytotoxi口tyassay. On Day 35 after starting 
continuous cultu口、 theyshowed Thyー1+,Lyt-1 .2+.3+ 
and ‘ぃ、ialり（ ,¥j l 「Jn］）凡y56 and 180, howeYer, Thy-1 
antigen J，引けmenegative. 
G-CTLL glioma-spc・citic cytotoxic T lymphocyte 
clone 
1礼lues孔restatistically signi五cant（本p<0.005).
IFN 産生が増強されることがわかった（Table5 A, 
B）.すなわち， a)G CTLL 1 (106/ml）を ConA (2, 5, 
10 μ.g/ml）で24時間刺激すると， その培養上清中（＂.：
IFN活性（各セ 1500,5600, 5000 U /ml）がみられた．
次に， G-CTLL1 (3×105/m／）を一定にして ConA 
(5 μ.g/m／）および下記の tumorantigenで刺激し IFN
の産生量を測定した.Cnn Aの場合， 150C mlであ




IFN活性が各々 140,156 U /mlと高値を示した．乙
れは， G-CTLLlが 203-gliomaと RSV-¥!に共通し
た7 ウスグリオ－7関連抗原に関与して IFNを産生
していることを示唆しているものと恩われる．
a), b）で産出された IFN活性は，抗7 ウス yIFN 


















40 20 10 5 2.5 ( x 10-3) 
dilution of anti-Lyt -2 antibody 
F沌.6. Blockinl{ of '"rgcl cel lysis by a1ti・f"yt 2 m11>10do1a！側 tibodiesiu /he 
α：bsence ofεomplemc111 
% blocking of cytotoxicity l>y anti-Lyt-2 manoclonal antil>odies is calcul-
ated as 100×（1 % cytatoxicity in the presence of antil>ody/% cytotoxi-
city in the absence of antibody). 




3. G-CTLL 1の invivoにおける抗腫場効果
i）麗疹中和試験（Winnザ peneutralization M回、）
E:T ratio= 10: 1の場合，全例が15週以上生存して
いる.E:T ratio=2: 1の場合では，MST,TOR, D ・1 
は各々 5.6週， 100%,5/5であった ；Tali!ν6）ー いずれ
の場合でも延命効果がみられた．
i）移入試験（systemicadoptive tr:rns!er a州，I¥'I 
a) 203-glioma細胞 5×105個を移植した担脳腫場
マウスに対し7日後に GCTLLl を静注した場合
(Table 7), 5×101または 2×107個では 1例 (10週自
に死亡）を除き全例15週以上生存している－ 1メ10＇ま
たは 5× io• 個では各々 :VIST は6_ 1, 5.9週， TOI<
はともに50$弘 D.T は4/8,5/10であった． すなわ
ち， 5× io• 個以上であれぽ延命効果がみられた．しか
しながら， 1×106個では MST,TDR, D T ！；）： ~キ勺
3.8週， lOOQづ＇8/8であり延命効果はみられなかった．
Fi色．苛ー A J!ay-C.γuen切ald-Ciemsasfαined .yt11a11lrifugcd pr-p.iratio1 of C-CTLL I 
cells ajteγ16 wuks of continuous ru!tuγぞi1ゎirro(.1！α.rrmfitα／／（｝｝／， x lユれlJ
G-CTLL gliama-spec泊ccytotoxic T lymphocyte clone 
791 日外宝第52巻第6号（昭和58年11月）
Table 6. lf'111n-l1'jJe nrn!ro/iこd同党 assayTable 5. ／う山／u(/1川 f of 1J11川 1111c IFλマ by(; CTLL 
lee/ls 
（人）
Con A 1μg rn/) 
IFN也activity¥ l'rn/} 












、 ． ????? 、
IFN activity ( l'マ 11/I 
Tumor cell lines 
E:T=O:l ! E:T 2:1 
203 glioma (H-2b) <2 140* 
B-16 1H :!b) <2 33 、M-12 1 1己bI <2 10 
EL4 1H-""1 く2 く2
R吋1’九I il ~は） く2 156* 
(' 1300 ill~ ト） く2 4 
P815 1H-2<l) <2 <2 
九人（ー l (H-2•) <2 戸2
Immune IF:¥ ,-a, produced ),y stimulating GぺTLL
1 cells with （九） mitogen ! cone ana,・alinλ、（ onλIor 
IHI tumor antigen. When 106/m/ (; ("fLL 1 cdl、
"< rピ culturedwith、はriou、concentrntionメ of Con 
主 themaximum activity of immune IFN wa' found 
to be released at 5 μ,g/ml Con A. ¥¥.hrn 3〆105/m!
じ CTLL1 cells 、necultured with Con人（5μ,g/m!J 
or tumorれ・1、（203-glioma. R~ ¥' -:'d I at E :T ratio of 
2 :1, a signi凸cantamount of immune I ド＇.＇＼ wa-. produced 
(*pく0.01). Therefore, G-CTLL 1 cel line appeared 
to叫＜rde immune IF>i in r円 l川口町 tomurine ghoma-
associated antigen-specific stimulation 
< • CT LL: glioma-specific cyt川oxic T lymphocyte 
clone. 
E :T: effector to target cel ratio. ND: not done. 
203-glioma: a methylcholanthrene induced ependymo-
blastoma of C57BL/6 mouse origin. 
B-16: a spontaneous malignant melanoma of C57BL/ 
6 mouse origin. 
Yi¥1-12: a methylcholanthrene-inducTCI tilrn出 trrnmaof 
C57BL/6 mouse origin. 
EL4: a benzopyrene-induced thymoma of C57BL/6 
mouse origin. 
RS¥' ¥1 a Schmitt-Ruppin Row, 、川《＇011辻、1ruャ Hl・
duced malignant glioma of （、3H/Hcmouse origin. 
C 1300: a spontaneous neuroblastoma of A/J 九x
mouse ongm. 
P815: a methylcholanthrcnc induced rn:cst川、ytornaof 
D !L¥;2J mouse origin. 
¥' .¥( 1：礼 moloneyleukemia vir山 inducedT cell lym-
l山＜＞maof 1¥/,.;n mouse origin. 
（｝（、lLL 1: Tumor ratio ,.;ur、1、aland ¥lortalit、
(1.c.: ：！ 八 10')
'¥!ST TDR I> '! 
10 : 1 15く 。。
2 : 1 5.6* 100 5 :0
0:1 3. 2 100 12'12 
A mixture of G-CTLL 1 and 5 X 105 203-glioma cells 
川（； CTLL 1: tumor cell ratios of 10:1 or 2・1¥・as 
i吋ectedintracranially. 人t10: 1 rλti《＞.al 6 mice ha＼＇仁
survived for over 15 weeks, and even at 2: 1 ratio ¥!ST 
was prolonged to 5.6 weeks Iヰp 0.051 
じ CTLL: glioma-spcci品c cytotoxic T lymphocyte 
clone. 
¥!ST・ median survival time. 
TD R: tumor death rate at 8 ＼＼＇札・k、
D/T: number of mice died 礼ftntumor cel inocula-
tion/ total number of m悶 inoculatedintracran凶 ly.






個を移入した場合， f手訂 M川、は2.（）司 3.6週， TOR









b) 203 glioma細胞 5X 105個を移植した担脳腫揚
7 ウスに対し種々の時期に（トCTLL1 1×107個を静
注し， （｝（、TLLl の投与時期による抗腫場効果の有
無を検索した（Table8). I ）ιl¥' 0では全iWIらしてい
る. I ｝川 3,5, 7では各勺＼ISl は6.6, 6.1, 6. 8週，




!i:!. 6, 2. 4週， TDRはともに110ιふ I> Iはともに
5/5であり，むしろ逆効果巾ISlの短縮）であった．
一方， Day7, 16 Iζ ！＇HSのみを静注しルこ場｛？＇ 各々
悪性グリオ ー＜＇ IL対する特異的免J＇~ JI,モ法への展望 795 
’E百ゐ1le7. Effects of adoptive tγansfeγ of G-CTLL 1 
on su開叩alof intγ町 rania!t抑制γ－bea：γi担E
智nue
Dose of tdaiYve transfer 
Sur、l、aland ¥lortalitv 
(i.v. on after i.e.) 恥1ST TDR D,T 
G-CTLL l: 5×107 15く 。1/14 
2×107 15く 。0/10 
1×107 6. 1* 50 4/8 
5×106 5.9ホ 50 5/10 
1×106 3.8 100 8/8 
一一一一一一
Ts 5×107 2. O** 100 5/5 
Tc 5×101 3.6 100 4/4 
Fーー一一一一
PBS only 3.3 100 4/4 
Various doses of G-CTLL 1 or immune T cells (Ts or 
Tc) were injected i.v. on Day 7 after i.e. of 5×105 203-
glioma cels. In groups of mice transferred with 5× 
107 and 2×107 G-CTLL 1 cels, al mice except one 
have survived for over 15 weeks. In groups of mice 
transfered with 1 x 107 and 5 x 106 G-CTLL 1 cels, 
¥!ST was prolonged to 6.1 and 5.9 weeks, respectively 
(*pく0.05)and each TDR was 50%. D/T was 4/8 
and 5/10, respectively and remaining 4 and 5 mice 
have survived for over 15 weeks, respectively. That 
is, considerable therapeutic effeets of G-CTLL 1 cels 
were found when transferred more than 5 x 10• G-CTLL 
1 cels 1ぜ Onthe other hand, survival was not affect-
ed in groups of mice transferred with l×106じ－CTLL
1 cels and 5 >:107 Tc cels. In groups of mice tran-
sfered with 5×10' Ts cels, however, survival was 
rather reduced (l¥IST; 2.0 weeks, TDR; 100~ ，打 D/T ;
5/5) （本Pく0.05),suggesting strongly that suppressor T 
cels or their precursor cels exist predominantly in T' 
cels and regulate immune responses in tumor-bearing 
ho札 Therefore,it seemed to be necessary to apply 
tumor・speci五ccytotoxic T lymphocyte clone such '" 
G-CTLL 1 cel line in adoptive immunotherapy. 
G・CTLL: glioma-speci品c cytotoxic T lymphocyte 
done. 
Tc: regional lymph node T cells in mice 14 days after 
s.c of 203-glima cels. Tc exhibited a peak cytotoxic 
acitvity in subcutaneous tumor-bearing mice73> 
Ts: splenic T cels in mice 3 days after s.c. of 203-
glioma cels. Ts exhibited a peak suppressor activity 
in subcutaneous tumor-bearin!l mice74). 
¥IST: median survival time.。
TOR: tumor death rate at 8 weeks. 
D/T: number of mice died after tumor cel inoculation/ 
total number of mice inoculated intracranialy. 
i.e: intracranial inoculation. 
‘.c: subcutaneous inoculation. 
¥!STは3.4, 2. 3 週， TDR はともlζ100~ぢ， ！） ／I は













している. 1×106個の場合も＇ :¥I討Tは6.4週， TDR
は40%, LJ • ' I 、 は4/10であり，延命効果がみられた．
JV.考察
悪性グリオー＂＜ Iζ対する免疫補助療法は，十数年前

























1. c; l'TLL lが syngeneicglioma (203 glioma）以
外の腫蕩に対し C'TL活性を示したのは， allogeneic
glioma (RS＼＇・1わのみであり， マウスグリオー7 ｛乙対
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T~弘、1le も. ( 'hronologiml study of adm111isl：γatio耳 ofG-CTLL 1 cells in the1γ吟euticeffects 






l’HS i TDR 
D/"l 
l>a¥' 0 Day3 




Survival and Mortality 
一一一
D川’5 Dav 7 D川 10 1>'1¥' 16 
6.0* 6.8* 2.6** 2.4＊ホ
60 40 100 100 
3/5 2/5 5/5 5/5 
← 一一一一一
ND 3.4 ND 2.3** 
ND 100 ND 100 
ND 4/4 ND 3/3 
1×107 G-CTLL 1 cels "ere injected i.v. various days after i.e. of 5×105 
203-glioma cells. On Day 0, al 5 mice have survived for over 10 
weeks. On Day 3, 5 and 7, ¥!ST was prolonged to 6.6, 6.0 and 6.8 weeb. 
r山 Pぞぐti、cly作pく0.05)and TDR was 40, 60 and 40°υ， respectively. D/T 
was 2/5, 3/5 and 2/5, respectively and remaining 3, 2 and 3 mice have 
survived for o、er10 weeks. That is, consideralbe therapeutic e仔ectsof 
G-CTLL 1 cells were found" hen transferred l×107G-CTLL1 cells i.v. by 
the 7th day after i.e. On the contrary, l¥IST was reduced to 2.6 and 2.4 
W山 b.respectively 円P-0.05）、 onDay 10 and 16, when thじintracranial 
pressure began to increase. F川 nwhen only PBS (1 m/) was injected i.Y 
into mice 16 days after i.e., MST was reduced to 2.3 weeks （料pく0.05).
Therefore, the therapeutic efects of G CTLL 1 cels were not detected 
when transferred more than 10 days after i.c. probably due to the further 
deterioration of IICP after i.v. injection. 
c;.('TLL glioma-speci五ccytotoxic T lymphocyte clone. 
I CP: increased intracranial pressure. 
i.e. intracranial inoculation. ¥!ST: median survival time. 
TDR: tumor death rate at 8 weeks. D/T: number of mice died after 
tumor cel inoculation/total number 。fmice inoculated intracran凶ly.
PBS: phosphate-bu仔eredsaline. '.i D not done. 
’E也、1也、－ Reiαtionship bet由自覚 thrrapeulireffects 
。fG-CJ LL 1 cells and dose of f抑制γ
cel inoodarwn 
i.c. dose Survival and Mortality 一一 一 一 一(i.v. 2×10') ¥'!ST TOR liT 
一一 一ー 一
2.5×105 I ioく 。0/6 
5.0×105 10く 。0/8 
1. 0×106 6.4* 40 4/10 
Various doses of tumor cells were inoculated intracra・ 
nialy and 7 days later 2×10＇心－ CTLL1 cels were 
injected i.v. In groups of mice inoculated with 2.5× 
105 or 5 x 105 tumor cells, al mice have叫 n・i1・ed for 
over 10 w刊 b. In a group of mice inoculated with 
I×106 tumor《ι・JI,.¥IS'l、W川 prolongedto 6.4 weeks 
けp<0.05)and TOR was 40%. D/T was 4/10 and 
remaining 6 mice h川 csurvived for over 10 ＼＼＇山 b
(;.cTLL: glioma spec凶C 円・totoxir T lymphocyte 
clone. 
MメT median survival time 
TDR: tumor death rate at 8 weeks 
D/T: number of mice died after tumor cel inocula 
tion/total number of mice inoculated intracranially. 
i.c.: intracranial inoculation. 
し腫湯特異性を有しているものと考えられた
2. 膜抗原は， Thy－ド， Lyt-1.z.+3+, asialo-GM，ーで
あり， CTLに特異的とされる抗7 ウス Lvt-2抗体単
独Kよる CTL活性阻止作用を受けたb 出 19・32・日仏品加．
3. 免疫 IFN産生能を有し mitogen(Con A）なら
びに tumorantigen (203-gliomaおよび RSV-M）刺
激で増強された.tumor antigen による免疫 IFN産
生は， G-CTLL 1 がマウスグリ寸ー7に対し麗蕩特





疫 IF＇.＜ 産生は H・2K. D抗原に関与していると報告
されている 3-1 • 最近， TCGF依存性 CTLクロー ン
株を用いた実験から CTL,TCGFおよび免疫 lFN 
の三者閣の相互関係，とくに CTLの分化・ 増殖に関
する研究が注目されている20,35，北町川れ70'. とのような





4. 凍結保存による G-CTLL1の増殖能， TCGF依
存性．腫湯特異性ならびに免疫 IFN産生能は維持さ
れている．
次に， G・CTLLlの invivo における抗l盛場効巣を




その投与数lζ依存していた． すなわち． 203-glioma 






































direct cytolytic effectを有し71に一方では， pre・CTL
から CTLへの分化誘導促進作用および CTL活性増
















をしている． このように単に長期培養 CTLの syste・
mic adoptive immunotherapyのみではその治療効果
は期待できず， systemicadoptive chemoimmunothe・ 
rapyの有用性が指摘されている．しかしながら，彼
らの実験系では，用いた腫蕩細胞株が advanceddis・ 
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わち，










graphyなどの方法を用い G・CTLLlのtarget organ 
すなわち脳への分布を確かめる必要がある．








4. Anti-idiotypic antibody21•5" ・ リンパ球クローンを
移入したためそれに対する抗体が産出され，~；,if~＇日’w:
クローンの抗腫場性を阻害してしまう可能性がある．




6. Presence of TCGF-inhibitor in the serum31＇：血
中IζTC<;Fィ活性阻害因子が存在しているため， リン
パ球クローンが速やかに消失してしまう可能性がある．


































2. G-CTLL 1が 203glioma以外の腫場株に対し
CTL活性を示したのは allogeneicglioma (RS¥' '.¥!) 
のみであった．故l乙 <;-CTLL 1 は7 ウスグリオ－
7 に対し腫場特異性を有しているものと思われた．膜
抗原は Thvード， Iλt-L-2.+3+,asialo心＇.＼！， であり，
CTL に特異的とされる抗7 ウス Iλト2抗体単独によ
るぐTL活性阻止作用を受けた．さらl亡 G一仁TLLl
は免疫 IFN産生能を有し， mitogen(Con A）ならび
に tumorantigen刺激で増強された．後者による免






3. G-CTLL 1の mvivoにおける抗腫蕩効果は，
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